180 related articles for article (PubMed ID: 38578116)
1. Mineralocorticoid receptor antagonists in kidney transplantation.
Kanbay M; Copur S; Mizrak B; Mallamaci F; Zoccali C
Eur J Clin Invest; 2024 Apr; ():e14206. PubMed ID: 38578116
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological interventions for heart failure in people with chronic kidney disease.
Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.
Mende CW; Samarakoon R; Higgins PJ
Am J Nephrol; 2023; 54(1-2):50-61. PubMed ID: 36682353
[TBL] [Abstract][Full Text] [Related]
6. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
7. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1129-1138. PubMed ID: 32675281
[TBL] [Abstract][Full Text] [Related]
9. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
10. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
[TBL] [Abstract][Full Text] [Related]
11. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
[TBL] [Abstract][Full Text] [Related]
12. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
[TBL] [Abstract][Full Text] [Related]
14. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
Sato A; Nishimoto M
Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
[TBL] [Abstract][Full Text] [Related]
16. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.
Ku E; Campese VM
Pediatr Nephrol; 2009 Dec; 24(12):2301-7. PubMed ID: 19347366
[TBL] [Abstract][Full Text] [Related]
17. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor antagonists in kidney transplantation: time to consider?
Girerd S; Jaisser F
Nephrol Dial Transplant; 2018 Dec; 33(12):2080-2091. PubMed ID: 29672718
[TBL] [Abstract][Full Text] [Related]
19. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
20. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.
Hiremath S; Fergusson DA; Fergusson N; Bennett A; Knoll GA
Am J Kidney Dis; 2017 Jan; 69(1):78-86. PubMed ID: 27712852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
